Effects of Polyquaternium- and Benzalkonium-Chloride-Preserved Travoprost on Ocular Surfaces: An Impression Cytology Study

被引:14
|
作者
Akcay, Betul Ilkay Sezgin [1 ]
Guney, Esra [1 ]
Bozkurt, Tahir Kansu [1 ]
Topal, Cumhur Selcuk [2 ]
Akkan, Julide Canan Umurhan [3 ]
Unlu, Cihan [1 ]
机构
[1] Umraniye Res & Training Hosp, Eye Clin, TR-34766 Istanbul, Turkey
[2] Umraniye Res & Training Hosp, Pathol Clin, TR-34766 Istanbul, Turkey
[3] Bezmialem Vakif Univ, Fac Med, Dept Ophthalmol, Istanbul, Turkey
关键词
CONJUNCTIVAL EPITHELIAL-CELLS; GLAUCOMA MEDICATIONS; OPHTHALMIC SOLUTIONS; CORNEAL; PRESERVATIVES; TOXICITY; TOLERABILITY; INFLAMMATION; HYPERTENSION; PREVALENCE;
D O I
10.1089/jop.2013.0248
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To compare the toxicity effect of polyquaternium (PQ) and benzalkonium chloride (BAK) preservation of travoprost on the ocular surface. Methods: This prospective study included 44 eyes of 44 patients with newly diagnosed glaucoma. Twenty-two patients used PQ-preserved travoprost (PQ group) and 22 patients used BAK-preserved travoprost (BAK group). To investigate the effect on the ocular surface, conjunctival impression cytology (IC) was performed at baseline and the 1- and 6-month follow-up visits. Additionally, the ocular surface disease index (OSDI) questionnaire, Schirmer I test, and tear break-up time (TBUT) measurement were administered at baseline, and at 1-, 3-, and 6-month follow-up visits. Results: While both groups showed statistically significant IC grade increases at 1 and 6 months when compared with baseline measurements, IC grades were significantly higher for patients using PQ-preserved travoprost compared with patients using BAK-preserved travoprost. The Schirmer I test and TBUT scores were not statistically significant between group 1 and BAK group at baseline and at 1-, 3-, and 6-month visits (P > 0.05). OSDI scores did not statistically differ at baseline and the 1-month measurements between the 2 groups (P > 0.05), but the 3- and 6-month OSDI scores were significantly higher for BAK group (P = 0.001). Differences in OSDI and Schirmer I test scores were statistically significant at 1, 3, and 6 months in both groups as compared with baseline values (P < 0.05). Statistically significant differences in the TBUT scores were seen for both groups at 3 and 6 months, while BAK group, but not PQ group, had insignificant score differences at 1 month as compared with baseline values of PQ group (P = 0.083). Conclusion: PQ-preserved travoprost was found to be safer and better-tolerated than BAK-preserved travoprost. PQ-preserved travoprost provided better ocular surface comfort, and therefore a better patient experience, which would likely result in higher treatment compliance.
引用
收藏
页码:548 / 553
页数:6
相关论文
共 24 条
  • [1] Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension
    Peace, James H.
    Ahlberg, Peter
    Wagner, Mathias
    Lim, John M.
    Wirta, David
    Branch, James D.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2015, 160 (02) : 266 - 274
  • [2] Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface - a multicentre randomized single-masked study
    Aihara, Makoto
    Oshima, Hiromi
    Araie, Makoto
    ACTA OPHTHALMOLOGICA, 2013, 91 (01) : e7 - e14
  • [3] Polyquad-Preserved Travoprost/Timolol, Benzalkonium Chloride (BAK)-Preserved Travoprost/Timolol, and Latanoprost/Timolol in Fixed Combinations: a Rabbit Ocular Surface Study
    Liang, Hong
    Brignole-Baudouin, Francoise
    Pauly, Aude
    Riancho, Luisa
    Baudouin, Christophe
    ADVANCES IN THERAPY, 2011, 28 (04) : 311 - 325
  • [4] Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study
    Hong Liang
    Françoise Brignole-Baudouin
    Aude Pauly
    Luisa Riancho
    Christophe Baudouin
    Advances in Therapy, 2011, 28 : 311 - 325
  • [5] The Effects of Latanoprost With Benzalkonium Chloride Versus Travoprost With SofZia on the Ocular Surface
    Rahmatnejad, Kamran
    Rapuano, Christopher J.
    Ichhpujani, Parul
    Wizov, Sheryl S.
    Moster, Marlene R.
    Hark, Lisa A.
    Katz, L. Jay
    EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE, 2018, 44 : S93 - S98
  • [6] Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
    Kanamoto, Takashi
    Kiuchi, Yoshiaki
    Tanito, Masaki
    Mizoue, Shiro
    Naito, Tomoko
    Teranishi, Shinichiro
    Hirooka, Kazuyuki
    Rimayanti, Ulfah
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2015, 31 (03) : 156 - 164
  • [7] From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability
    Rossi, Gemma Caterina Maria
    Scudeller, Luigia
    Rolle, Teresa
    Pasinetti, Gian Maria
    Bianchi, Paolo Emilio
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (05) : 619 - 623
  • [8] Impression cytology study of epithelial phenotype of ocular surface reconstructed by preserved human amniotic membrane
    Prabhasawat, P
    Tseng, SCG
    ARCHIVES OF OPHTHALMOLOGY, 1997, 115 (11) : 1360 - 1367
  • [9] Effects of Benzalkonium Chloride-Preserved, Polyquad-Preserved, and sofZia-Preserved Topical Glaucoma Medications on Human Ocular Epithelial Cells
    Ammar, David A.
    Noecker, Robert J.
    Kahook, Malik Y.
    ADVANCES IN THERAPY, 2010, 27 (11) : 837 - 845
  • [10] Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells
    David A. Ammar
    Robert J. Noecker
    Malik Y. Kahook
    Advances in Therapy, 2010, 27 : 837 - 845